Chagas disease, caused by Trypanosoma cruzi, affects six to seven million people worldwide. Treatment is based on benznidazole, producing several side effects and debatable efficacy, highlighting the need for new alternative drugs. We investigated the activity of four C-4 functionalized azlactone derivatives (EPA-27, EPA-35, EPA-63 and EPA-91) as potential T. cruzi inhibitors. Screening with epimastigotes indicated EPA-35 as the best compound (IC 50 /24 h: 33 μM). This compound was 14.1 times more potent against intracellular amastigotes (IC 50 /24 h: 2.34 μM). Treatment of infected Vero cells for 72 h (up to 30 μM EPA-35) resulted in a dose-dependent decrease in number of trypomastigotes and amastigotes released in the supernatant, but the amastigote/trypomastigote ratio remained constant, indicating that amastigote growth was disturbed, but cell differentiation was unaffected. Analysis of treated epimastigotes by flow cytometry indicated that the plasma membrane remained intact, but there was a significant decrease in mitochondrial membrane potential. The pattern of cell distribution in the cell cycle stages (G1, G2, M) was unaltered in treated epimastigotes, indicating a trypanocidal rather than a trypanostatic activity. Scanning electron microscopy and flow cytometry showed epimastigotes with a round shape and decrease in cell size. Taken together, our data indicate that the EPA-35 is effective against T. cruzi. Synthetic transformation of EPA-35 into other derivatives may provide promising compounds for further evaluation against this parasite.
INTRODUCTION
The flagellate protozoan Trypanosoma cruzi causes Chagas disease, which is a chronic disease endemic in Latin America, affects six to seven million people worldwide (WHO 2016) . Chagas disease represents a significant human health problem on the American continent in terms of both its socioeconomic impact and geographical distribution (Bermudez et al. 2016) .
Human disease results from invasion of the natural ecotopes and establishment of vectors in human dwellings found in poor socioeconomic conditions of rural populations (Urbina 2010 ). Blood transfusion, congenital transmission, and increased migration rates have promoted the spread of the disease to nonendemic regions, such as the United States and Western Europe (Schmunis and Yadon 2010; Urbina 2010; WHO 2016) . Currently, benznidazole (BZN) and nifurtimox (NFX) are available for Chagas disease treatment during acute and initial chronic phases (Coura 2009; Urbina 2010) . However, BZN and NFX do not satisfy the World Health Organization (WHO) criteria for an ideal drug: (i) parasitological cure in acute and chronic cases of infection;
(ii) effectiveness in a single dose or a few doses; (iii) accessibility to patients; (iv) no teratogenic or side effects; (v) no need for hospitalization of patients for treatment; (vi) no induction of resistance to the etiological agent (Coura 2009; Urbina 2010) .
With new cases in endemic regions and recent cases of the disease spreading into non-endemic regions (WHO 2016) , new drugs are needed to effectively treat both the disease and prophylaxis of T. cruzi in blood banks. Therefore, alternative compounds to treat Chagas disease are needed.
Oxazolones are five-membered heterocyclic compounds with nitrogen and oxygen as heteroatoms (Bala, Saini and Kamboj 2011; Sharma et al. 2015) . Oxazolones are important synthons for the synthesis of biologically active compounds and key pharmacophores of synthesized drugs (Sharma et al. 2015) . Oxazol-5(4H)-ones, also known as azlactones, are readily prepared from N-protected amino acids (Ávila et al. 2013 Pereira et al. 2014; Barbosa, Teixeira and Amarante 2015; Pinheiro et al. 2016) . Because of their easy availability and diverse reactions, azlactones have many possibilities as building blocks for many important commercial products, such as drugs (Mukerjee 1987; Bala, Saini and Kamboj 2011) .
Erlenmeyer azlactones have been involved in a series of biological activities, with anti-inflammatory, antimicrobial, anti-HIV, anti-angiogenic, anticonvulsant and antitumoral properties (Bala, Saini and Kamboj 2011) . Some oxazolone derivatives have tyrosinase inhibitory properties (Khan et al. 2006; Abdel-Aty 2009; Bala et al. 2012 ) and fungitoxic effect, probably due to their mutagenic potential during in vitro DNA synthesis (Abdel-Aty 2009). They also exhibit promising photochemical activity and cyclooxygenase-2 inhibitory property (Bala et al. 2012) . Spirocyclopropyl oxazolones are a family of compounds that represents a class of inhibitors of herpes proteases (Witvrouw et al. 1999 ).
Here we investigated whether C-4 functionalized azlactone derivatives have trypanocidal activity. As far as we know, this is the first report regarding the anti-trypanosomatid activity of these compounds. The activity of four synthetic azlactone derivatives was here evaluated on the epimastigote and amastigote forms of T. cruzi.
MATERIAL AND METHODS

Compounds
The azlactone derivatives EPA-27, EPA-35, EPA-63 and EPA-91 were synthesized as previously described (products 3g, 3e, 3a and 3f, respectively) byÁvila et al. (2013) . In summary, the reactions were performed using azlactone derivatives, enones and catalytic amounts of (±)-camphorsulfonic acid under room temperature with toluene as the solvent.
For bioassays, compounds were first diluted to 100 mM in dimethyl sulfoxide (DMSO) and then diluted to 10 mM in DMSO. This second solution was further diluted to several concentrations in Liver Infusion Tryptose (LIT, Camargo 1964 ) medium for the experiments, with final concentration of DMSO never exceeding 1%.
Vero cells
Vero cells (ATCC: CCL-81) were kept at 37
• C and 5% CO 2 in a 
Parasites
Trypanosoma cruzi clone Dm28c epimastigotes were kept at 28
• C in LIT medium supplemented with 10% FBS and passaged every 3 to 4 days. Cell-derived trypomastigotes were collected 3 to 4 days post-infection from the supernatant of infected Vero cell cultures by centrifugation for 10 min at 3000 × g. Cells were resuspended in DMEM and used for host cell re-infections at a ratio of 10 trypomastigotes per cell.
To obtain intracellular amastigotes, Vero cells previously seeded in 24-well plates were infected with trypomastigotes. After 4 h, wells were washed with PBS and kept for 24 h at 37
• C and 5% CO 2 in 1 ml of DMEM and then used in the experiments.
Cytotoxicity assay
Vero cell cultures were incubated for 24 or 72 h with serial dilutions of EPA-35 (500-15.6 μM), under the same conditions described above. For BZN, the tested concentrations were 1, 10, 100 or 1000 μg ml −1 (3.84, 38.42, 384.27 and 3842.70 μM, respectively). Cytotoxicity (CC 50 ) was evaluated by MTT (Sigma-Aldrich, St. Louis, MO, USA) colorimetric assay, as previously described (Azeredo et al. 2014) . The concentration that kills 50% of the cell population (CC 50 ) after 24 or 72 h treatment was estimated from an average of a technical triplicate by non-linear regression using GraphPad Prism 5.0 software (GraphPad Software Inc., La Jolla, CA, USA).
Screening compounds against Trypanosoma cruzi epimastigotes
To calculate the inhibitory concentration that kills 50% of the cell population (IC 50 ) after 24 h, 3-day-old culture epimastigotes in LIT medium (1 × 10 7 cells ml −1 ) were seeded into 96-well plates (180 μl well −1 ) and incubated with serial dilutions (100-12.5 μM)
of EPA-27, EPA-35, EPA-63 or EPA-91. BZN (50-6.25 μM) and 1% DMSO were used as positive and negative controls, respectively. The antiparasitic activity was assessed by the MTT assay as previously described (Azeredo et al. 2014) . The IC 50 /24 h value was estimated from a technical triplicate by non-linear regression using the GraphPad Prism 5.0 software. The compound with the highest selectivity index (SI is CC 50 /24 h / IC 50 /24 h) was selected for further analysis on amastigotes.
Activity on Trypanosoma cruzi intracellular amastigotes
To assess the effect on intracellular amastigotes, infected Vero cells were incubated for 24 h with serial dilutions of , in a final volume of 200 μl well −1 . BZN (serially diluted from 60 to 7.5 μM) and 1% DMSO were used as controls. The plates were then washed with PBS, fixed with methanol and stained with Giemsa (Merck, Darmstadt, Germany). To evaluate trypanocidal activity, 100 host cells per well were randomly selected by inverted microscopy and the total number of intracellular amastigotes was estimated. The values obtained were expressed as percent inhibition [PI is 100 − (T/C × 100)], where T is the average number of total intracellular amastigotes in treated cells and C is the average number of total intracellular amastigotes in control cells. The IC 50 /24 h values were estimated from the PI values obtained from a technical triplicate and analyzed using the GraphPad Prism 5.0 software.
To assess the activity of EPA-35 on the intracellular differentiation (amastigote to trypomastigote), infected Vero cell cultures were treated with 3.75-30 μM EPA-35. Supernatants were collected after 72 h and the number of released trypomastigotes and amastigotes was estimated by counting in a Neubauer chamber. The amastigote to trypomostigote ratio was determined with CompuSyn software (ComboSyn Inc., Paramus, NJ, USA). Host cell cytotoxicity after 72 h was determined as described above. Experiments were performed in technical triplicate, and statistical analysis was made using ANOVA followed by the Tukey-Kramer multiple comparisons test with GraphPad Prism 5.0 software.
Flow cytometry
All experiments were performed with a FACScanto II (BD Biosciences, San Diego, CA, USA) flow cytometer. Approximately 20 000 events were collected for each assay (SSC × FSC visualization of population, ungated). Data were analyzed with FlowJo software (FlowJo, Ashland, OR, USA). Statistical analysis was performed using ANOVA followed by a Tukey-Kramer multiple comparisons test using GraphPad Prism 5.0 software for all parameters evaluated. All experiments were performed in technical triplicate. For all experiments, 1 × 10 6 epimastigotes were previously treated for 24 h with 15, 30 or 50 μM EPA-35 or else with 33 μM or 66 μM EPA-35; the epimastigotes were then centrifuged for 1 min at 7000 × g and washed with 1 ml of PBS.
To estimate mitochondrial membrane potential (ψm), treated epimastigotes were incubated for 15 min at 28
• C with 10 μg ml −1 rhodamine-123 (Rhd) and then washed three times in PBS (Kessler et al. 2013) . Fluorescence was quantified with a 530/30 nm filter. Positive control was made with 50 μM carbonyl cyanide m-chlorophenyl hydrazine (CCCP; Sigma, St Louis, MO, USA). Cell size alteration was estimated from the FSC-A parameter.
To determine plasma membrane integrity, epimastigotes were rinsed with PBS and then stained with 5 μg ml −1 propidium iodide (PI) for 10 min at room temperature (Kessler et al. 2013) . PI staining was quantified with a 585/42 nm filter.
To evaluate the cell division cycle, epimastigotes were suspended in 1 ml of DNA staining solution (3.4 mM Tris-HCl, 0.075 mM PI, 0.1% NP-40, 10 mM NaCl and 700 U/L RNase A), as previously described (Di Paola et al. 2010) . Cells were kept on ice until analysis. Analysis were performed on single-epimastigotes gate (FSC-W × FSC-H), for exclusion of doublets.
Scanning electron microscopy
Epimastigotes were treated for 24 h with 33 μM or 66 μM EPA-35, washed with PBS and fixed for 40 min with 2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer pH 7.2. The parasites were washed in the same buffer and adhered for 10 min to glass coverslips coated with 0.1% poly-l-lysine. They were then post-fixed for 10 min in 1% osmium tetroxide, dehydrated in ascending acetone series and critical point dried. The coverslips were adhered to scanning electron microscopy (SEM) stubs and coated with a 20-nm-thick gold layer. Samples were observed in a Jeol JSM 6010PLUS-LA scanning electron microscope at 20 kV.
RESULTS AND DISCUSSION
The azlactone derivatives EPA-27, EPA-35, EPA-63 and EPA-91 were successfully synthesized under catalytic, metal-free conditions. The yields were moderate to good, ranging from 60% to 80%, in near perfect control of both regio-and diastereoselectivities (only 1.4-addition and >20:1 dr). Chemical structures of the products are shown in All four compounds were first screened against Trypanosoma cruzi epimastigotes. After incubation for 24 h, the most effective compound was EPA-35 (Table 1 Because EPA-35 gave the best results against epimastigotes, it was further evaluated in vitro on intracellular amastigotes in which it was 14.1 times more potent, when compared to the activity on epimastigotes ( An increase in selectivity of essential oils toward amastigotes has already been shown (Santoro et al. 2007; Medeiros et al. 2011; Azeredo et al. 2014) , highlighting the need to evaluate candidate compounds on the more clinically relevant amastigotes. Regarding the chemical structure of the four synthesized azlactone analogs, the presence of a methyl group at the stereogenic center (C-4 substitution) and a conjugate double bond seems pivotal for the highest biological activity of EPA-35. Oxazolones are used in the manufacturing of various biologically active drugs and the substitution of a functional group at the C-4 and C-2 positions is vital in the activity of these compounds (Bala, Saini and Kamboj 2011) . The four functionalized azlactones used here were expected to present a higher extension of conjugation, due to the presence of one more double bond external to the heterocyclic ring. The best activity of EPA-35 could be attributed to its higher conjugation and to a more appropriate molecular conformation due to the presence of a methyl group as side chain. It has been shown that azlactones present mutagenic potential on DNA synthesis (Abdel-Aty 2009) and are potent inhibitors of methionylRNA synthetase (Abdel-Aty 2009). Therefore, EPA-35 could be acting on DNA synthesis of the parasites.
Infected Vero cells were submitted to EPA-35 treatment (up to 30 μM), and the the release of amastigotes/trypomastigotes in the supernatant was quantified after 72 h of incubation. There was a dose-dependent decrease in the mean parasite count ( Fig. 2A) , but the amastigotes to trypomastigote ratio remained constant (Fig. 2B) , indicating that the effect was on amastigotes growth, but not on amastigote differentiation. Incubation of uninfected Vero cells for 72 h with EPA-35 resulted in a CC 50 /72 h value of 404.6 μM, whereas BZN did not induce cytotoxicity in concentrations as high as 3842.70 μM. Therefore, the dosedependent decrease in the mean parasite number in the supernatant of infected cultures cannot be attributed to cytotoxicity to the host cells.
Cell division cycle analysis by flow cytometry with epimastigotes (T. cruzi proliferative forms, as amastigotes) showed that EPA-35 did not arrest the cell cycle at any phase after a 24 h treatment (Fig. S3A , Supporting Information), indicating that cell division was not affected. Counting the number of epimastigotes after a 24 h treatment showed a reduction in cell number (Fig. S3B ). This result also confirms that the decrease in trypomastigotes/amastigotes number in the supernatant of infected Vero cell cultures was probably due to a trypanocidal activity of the compound on the intracellular amastigotes, rather than trypanostatic.
Analysis of epimastigotes treated with EPA-35 and then stained with Rhd showed a significant decrease in the ψmas measured by flow cytometry (Fig. 3A and B) , indicating that EPA-35 acts on the parasite mitochondrion. Treatment with BZN also induced a significant alteration in ψm ( Fig. 3D and E) , but only at 24 μM (2 × IC 50 /24 h). However, the possibility remains that this is a downstream effect due to another target. Trypanosomatids have to maintain the transmembrane potential of a single mitochondrion for parasite survival (Garcia et al. 2013; MennaBarreto and Castro 2014) , which makes this organelle an important target for drug therapy. EPA-35-treated epimastigotes incubated with PI showed no DNA labeling, indicating that the parasite cell membrane remained intact after 24 h treatment (Fig. 3C) . BZN treatment also did not cause any significant change in PI staining (Fig. 3F) .
Treatments with 30 μM or 50 μM EPA-35 led to an 8-fold increase in the number of smaller cells, when compared to untreated epimastigotes (Fig. 4) . By SEM, T. cruzi epimastigotes treated with 33 μM EPA-35 (IC 50 /24 h) presented a round shape with an apparent decrease in cell size ( Fig. 5C and D) when compared to untreated control cells (Fig. 5A and B) . When cells were treated with 66 μM (2 × IC 50 /24 h), the same morphological alterations were observed ( Fig. 5E and F) . Possibly some cytoskeleton changes occur in treated parasites resulting in loss of normal morphology with rounded/wrinkled appearance, that leads to the decrease in cell size observed by cytometry (FSC) The structural alteration is not due to cytoplasmic leakage from a pore phenotype in the plasma membrane, because this phenotype was not observed by flow cytometry (PI) or morphologically by SEM.
Lack of PI staining, added to decrease in cell size and ψm disruption, could indicate apoptosis as cell death mechanism (Jiménez-Ruiz et al. 2010; Proto, Coombs and Mottram 2013) . However, it has been suggested that cell death in parasitic protozoa should be classified as non-regulated necrosis, since no death receptors and signaling pathways consistent with any type of programmed cell death are efficiently identified in these organisms (Proto, Coombs and Mottram 2013) .
In conclusion, our data indicate that the azlactone derivative EPA-35 was active against T. cruzi. Although this does not justify clinical use in EPA-35 current form, EPA-35 is a promising compound for further evaluation against this parasite. Further studies on the synthetic transformation of EPA-35 into other derivatives may yield a compound with reduced cytotoxicity and enhanced activity against T. cruzi.
